Cara Therapeutics Management
Management criteria checks 2/4
Cara Therapeutics' CEO is Chris Posner, appointed in Nov 2021, has a tenure of 2.42 years. total yearly compensation is $2.92M, comprised of 24.9% salary and 75.1% bonuses, including company stock and options. directly owns 0.19% of the company’s shares, worth $72.12K. The average tenure of the management team and the board of directors is 2.3 years and 4.8 years respectively.
Key information
Chris Posner
Chief executive officer
US$2.9m
Total compensation
| CEO salary percentage | 24.9% |
| CEO tenure | 2.4yrs |
| CEO ownership | 0.2% |
| Management average tenure | 2.3yrs |
| Board average tenure | 4.8yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$3m | US$728k | -US$119m |
| Sep 30 2023 | n/a | n/a | -US$117m |
| Jun 30 2023 | n/a | n/a | -US$112m |
| Mar 31 2023 | n/a | n/a | -US$84m |
| Dec 31 2022 | US$3m | US$700k | -US$85m |
| Sep 30 2022 | n/a | n/a | -US$89m |
| Jun 30 2022 | n/a | n/a | -US$66m |
| Mar 31 2022 | n/a | n/a | -US$93m |
| Dec 31 2021 | US$10m | US$116k | -US$88m |
| Sep 30 2021 | n/a | n/a | US$24m |
| Jun 30 2021 | n/a | n/a | US$8m |
| Mar 31 2021 | n/a | n/a | US$14m |
| Dec 31 2020 | US$280k | n/a | US$8m |
| Sep 30 2020 | n/a | n/a | -US$99m |
| Jun 30 2020 | n/a | n/a | -US$115m |
| Mar 31 2020 | n/a | n/a | -US$113m |
| Dec 31 2019 | US$302k | n/a | -US$106m |
| Sep 30 2019 | n/a | n/a | -US$98m |
| Jun 30 2019 | n/a | n/a | -US$85m |
| Mar 31 2019 | n/a | n/a | -US$79m |
| Dec 31 2018 | US$494k | n/a | -US$74m |
Compensation vs Market: Chris's total compensation ($USD2.92M) is above average for companies of similar size in the UK market ($USD346.19K).
Compensation vs Earnings: Chris's compensation has increased whilst the company is unprofitable.
CEO
Chris Posner (53 yo)
2.4yrs
Tenure
US$2,922,469
Compensation
Mr. Christopher A. Posner also known as Chris, served as Independent Director of Zevra Therapeutics, Inc. (formerly known as KemPharm, Inc.), since November 2022. He serves as President and Chief Executive...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.4yrs | US$2.92m | 0.19% $ 72.1k | |
| Chief Financial Officer | 1.6yrs | US$1.24m | 0.015% $ 5.5k | |
| Co-Founder & Senior Advisor | 2.4yrs | US$10.20m | no data | |
| Chief Strategy Officer & Head of Investor Relations | 2.3yrs | no data | no data | |
| Chief Compliance Officer | 7.4yrs | US$1.59m | 0.15% $ 55.8k | |
| Senior Vice President of Regulatory Affairs & QA | 2.2yrs | no data | no data | |
| Manager of Investor Relations | no data | no data | no data |
2.3yrs
Average Tenure
56.5yo
Average Age
Experienced Management: 0HTC's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 5.7yrs | US$2.92m | 0.19% $ 72.1k | |
| Independent Chairman & Lead Independent Director | 13.8yrs | US$519.99k | 0.082% $ 30.8k | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 9.8yrs | US$272.49k | 0.028% $ 10.6k | |
| Independent Director | less than a year | US$376.01k | 0% $ 0 | |
| Independent Director | 3.8yrs | US$262.49k | 0.028% $ 10.6k | |
| Independent Director | 1.4yrs | US$254.99k | 0% $ 0 |
4.8yrs
Average Tenure
60.5yo
Average Age
Experienced Board: 0HTC's board of directors are considered experienced (4.8 years average tenure).